JP2017511133A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511133A5
JP2017511133A5 JP2016559234A JP2016559234A JP2017511133A5 JP 2017511133 A5 JP2017511133 A5 JP 2017511133A5 JP 2016559234 A JP2016559234 A JP 2016559234A JP 2016559234 A JP2016559234 A JP 2016559234A JP 2017511133 A5 JP2017511133 A5 JP 2017511133A5
Authority
JP
Japan
Prior art keywords
eza
polypeptide
amino acid
seq
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016559234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511133A (ja
Filing date
Publication date
Priority claimed from GBGB1405784.8A external-priority patent/GB201405784D0/en
Application filed filed Critical
Publication of JP2017511133A publication Critical patent/JP2017511133A/ja
Publication of JP2017511133A5 publication Critical patent/JP2017511133A5/ja
Pending legal-status Critical Current

Links

JP2016559234A 2014-03-31 2015-03-31 新規の方法、ポリペプチド、及びその使用 Pending JP2017511133A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405784.8 2014-03-31
GBGB1405784.8A GB201405784D0 (en) 2014-03-31 2014-03-31 Novel methods, polypeptides and uses thereof
PCT/GB2015/051006 WO2015150799A1 (en) 2014-03-31 2015-03-31 Novel methods, polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2017511133A JP2017511133A (ja) 2017-04-20
JP2017511133A5 true JP2017511133A5 (https=) 2018-05-17

Family

ID=50737758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016559234A Pending JP2017511133A (ja) 2014-03-31 2015-03-31 新規の方法、ポリペプチド、及びその使用

Country Status (9)

Country Link
US (1) US20170107503A1 (https=)
EP (1) EP3125926A1 (https=)
JP (1) JP2017511133A (https=)
CN (1) CN106257988A (https=)
AU (1) AU2015242380A1 (https=)
BR (1) BR112016022584A2 (https=)
GB (1) GB201405784D0 (https=)
RU (1) RU2016142580A (https=)
WO (1) WO2015150799A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120866A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
US20200015499A1 (en) * 2017-03-15 2020-01-16 Dupont Nutrition Biosciences Aps Trypsin-like serine proteases and uses thereof
GB201800274D0 (en) 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201801982D0 (en) 2018-02-07 2018-03-28 Enzymatica Ab Novel treatments
EP3969579A1 (en) * 2019-05-13 2022-03-23 Bioseutica B.V. Purified fish proteases with high specific activities and its process of production
KR20220157997A (ko) 2020-03-23 2022-11-29 케레시스 아게 항균 용액 및 이것을 감염의 치료 또는 예방에 사용하는 방법
CN115666512A (zh) * 2020-05-13 2023-01-31 智密科技公司 用于治疗微生物感染的蛋白酶制剂
CN115778864B (zh) * 2022-12-12 2024-04-19 广州市美夫兰化妆品有限公司 一种祛斑净白抗皱冻干粉

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
RU2264824C2 (ru) * 1999-06-18 2005-11-27 Йон Браги БЬЯРНАСОН Сериновые протеиназы рыб и их фармацевтическое и косметическое применение
WO2012104099A1 (en) * 2011-02-04 2012-08-09 Glucometrix Ag Process for the production of recombinant trypsin
ES2890555T3 (es) * 2014-01-29 2022-01-20 Enzymatica Ab Tripsina de bacalao para uso en el tratamiento de infecciones microbianas en un sujeto con inmunodeficiencia

Similar Documents

Publication Publication Date Title
JP2017511133A5 (https=)
Waasdorp et al. The bigger picture: why oral mucosa heals better than skin
Adnan et al. Antimicrobial peptides in wound healing and skin regeneration: Dual roles in immunity and microbial defense
Fabbri et al. Escherichia coli cytotoxic necrotizing factor 1 (CNF1): toxin biology, in vivo applications and therapeutic potential
Gong et al. Effective treatment of Helicobacter pylori infection using supramolecular antimicrobial peptide hydrogels
Ling et al. Cathelicidins from the bullfrog Rana catesbeiana provides novel template for peptide antibiotic design
JPWO2019156137A5 (https=)
ES2813551T3 (es) Nuevas isoformas de tripsina y su uso
RU2016142580A (ru) Новые способы, полипептиды и их применение
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
JP2017529326A5 (https=)
MX341317B (es) Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
Portaro et al. The Mycobacterium leprae hsp65 displays proteolytic activity. Mutagenesis studies indicate that the M. leprae hsp65 proteolytic activity is catalytically related to the HslVU protease
Seo et al. Antimicrobial activity and action mechanisms of Arg-rich short analog peptides designed from the C-terminal loop region of American oyster defensin (AOD)
JP2018533970A5 (https=)
CN108530527B (zh) 一种多肽oa-gl21及其提纯方法与应用
WO2019029129A1 (zh) 一种针对IL-17和TNF-α的双特异性融合蛋白
JP2017513849A5 (https=)
Dzurová et al. Cathelicidins: opportunities and challenges in skin therapeutics and clinical translation
Mormile et al. The Benefits of Water from Nitrodi’s Spring: The In Vitro Studies Leading the Potential Clinical Applications
Ouyang et al. High therapeutic index α-helical AMPs and their therapeutic potential on bacterial lung and skin wound infections
Maystrenko et al. The addition of a synthetic LPS-targeting domain improves serum stability while maintaining antimicrobial, antibiofilm, and cell stimulating properties of an antimicrobial peptide
JP2009544304A5 (https=)
Scavello et al. Recent advances in multifunctional antimicrobial peptides as immunomodulatory and anticancer therapy: chromogranin a-derived peptides and dermaseptins as endogenous versus exogenous actors